Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration.

[1]  A. Yoshida,et al.  Relationship between choroidal thickness and choroidal circulation in healthy young subjects. , 2012, American journal of ophthalmology-glaucoma.

[2]  Valerie Quarmby,et al.  Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. , 2007, Experimental eye research.

[3]  Michael D. Ober,et al.  Choroidal infarction following photodynamic therapy with verteporfin. , 2005, Archives of ophthalmology.

[4]  Usha Chakravarthy,et al.  The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. , 2008, Ophthalmology.

[5]  K. Freund,et al.  Intraocular Pressure in Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Aflibercept or Ranibizumab. , 2015, Ophthalmology.

[6]  A. Tsujikawa,et al.  One-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome. , 2015, American journal of ophthalmology.

[7]  A. Tsujikawa,et al.  Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization , 2012, Clinical ophthalmology.

[8]  Christian Simader,et al.  Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. , 2012, Ophthalmology.

[9]  Y. Ikuno,et al.  Choroidal thickness in healthy Japanese subjects. , 2010, Investigative ophthalmology & visual science.

[10]  R. Spaide,et al.  A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. , 2009, American journal of ophthalmology.

[11]  S. Michels,et al.  Change in choroidal thickness after intravitreal aflibercept in pretreated and treatment-naive eyes for neovascular age-related macular degeneration , 2015, British Journal of Ophthalmology.

[12]  Haitao Li,et al.  Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. , 2015, Ophthalmology.

[13]  Se Woong Kang,et al.  Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. , 2011, Ophthalmology.

[14]  I. Maruko,et al.  [Retinal and choroidal thickness changes following intravitreal ranibizumab injection for exudative age-related macular degeneration]. , 2012, Nippon Ganka Gakkai zasshi.

[15]  I. Maruko,et al.  Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. , 2011, American journal of ophthalmology.

[16]  Jiong Yan,et al.  Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. , 2013, American journal of ophthalmology.

[17]  L. Damico,et al.  DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006, Retina.

[18]  Marissa L. Weber,et al.  Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab , 2013, British Journal of Ophthalmology.

[19]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[20]  V. Mahajan,et al.  Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. , 2013, American journal of ophthalmology.

[21]  Hideki Koizumi,et al.  Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results. , 2012, Ophthalmology.

[22]  L. Rangell,et al.  PHARMACOKINETICS AND RETINAL DISTRIBUTION OF RANIBIZUMAB, A HUMANIZED ANTIBODY FRAGMENT DIRECTED AGAINST VEGF-A, FOLLOWING INTRAVITREAL ADMINISTRATION IN RABBITS , 2007, Retina.

[23]  R. Kawasaki,et al.  Subfoveal choroidal thickness in typical age-related macular degeneration and polypoidal choroidal vasculopathy , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[24]  H. Kim,et al.  Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation. , 2015, American journal of ophthalmology-glaucoma.

[25]  Jae Hui Kim.  Short-Term Changes in Choroidal Thickness After Aflibercept Therapy for Neovascular Age-Related Macular Degeneration. , 2015, American journal of ophthalmology.

[26]  P. Kaiser,et al.  Aflibercept for age-related macular degeneration: a game-changer or quiet addition? , 2012, American journal of ophthalmology.

[27]  J. Slakter,et al.  INDOCYANINE GREEN VIDEOANGIOGRAPHY OF IDIOPATHIC POLYPOIDAL CHOROIDAL VASCULOPATHY , 1995, Retina.

[28]  R. Spaide,et al.  Enhanced depth imaging spectral-domain optical coherence tomography. , 2008, American journal of ophthalmology.

[29]  M. Stewart.  Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug , 2012, British Journal of Ophthalmology.

[30]  S. Kinoshita,et al.  Relationship between clinical characteristics of polypoidal choroidal vasculopathy and choroidal vascular hyperpermeability. , 2013, American journal of ophthalmology.

[31]  P. Rosenfeld,et al.  Predicted biological activity of intravitreal VEGF Trap , 2008, British Journal of Ophthalmology.

[32]  S. Liu,et al.  Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. , 1993, The American journal of physiology.

[33]  U. Schmidt-Erfurth,et al.  Photodynamic effects on choroidal neovascularization and physiological choroid. , 2002, Investigative ophthalmology & visual science.

[34]  J. Williamson,et al.  Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF. , 1999, Investigative ophthalmology & visual science.

[35]  Philip J Rosenfeld,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[36]  Gerald Seidel,et al.  Circadian macular volume changes in the healthy human choroid. , 2015, American journal of ophthalmology.

[37]  H. Koizumi,et al.  Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results. , 2016, Ophthalmology.

[38]  G. Yancopoulos,et al.  VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Slakter,et al.  RETINAL ANGIOMATOUS PROLIFERATION IN AGE–RELATED MACULAR DEGENERATION , 2001, Retina.

[40]  U. Schraermeyer,et al.  Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes , 2014, British Journal of Ophthalmology.

[41]  Yoshiaki Yasuno,et al.  Reproducibility of retinal and choroidal thickness measurements in enhanced depth imaging and high-penetration optical coherence tomography. , 2011, Investigative ophthalmology & visual science.

[42]  S. Kang,et al.  Thinner choroid and greater drusen extent in retinal angiomatous proliferation than in typical exudative age-related macular degeneration. , 2013, American journal of ophthalmology.

[43]  S. Kinoshita,et al.  SUBFOVEAL CHOROIDAL THICKNESS IN RETINAL ANGIOMATOUS PROLIFERATION , 2014, Retina.

[44]  J. Slakter,et al.  VISUAL AND ANATOMICAL OUTCOMES OF INTRAVITREAL AFLIBERCEPT IN EYES WITH PERSISTENT SUBFOVEAL FLUID DESPITE PREVIOUS TREATMENTS WITH RANIBIZUMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2013, Retina.

[45]  Ivana K. Kim,et al.  Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. , 2013, American journal of ophthalmology.

[46]  G. Yancopoulos,et al.  Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab , 2012, Angiogenesis.

[47]  H. Oyamada,et al.  Choroidal thickness changes after intravitreal ranibizumab and photodynamic therapy in recurrent polypoidal choroidal vasculopathy. , 2013, American journal of ophthalmology.